Haemonetics Expands VASCADE MVP Vascular Closure Device to Europe

Haemonetics Corp. announced patents were treated with the company’s VASCADE MVP venous vascular closure system in Germany. This is the first use of the VASCADE system portfolio in a European country.
 
VASCADE was engineered for small-bore femoral arterial and venous closure in interventional cardiology and peripheral vascular procedures. VASCADE MVP was designed for mid-bore, multi-access femoral venous closure for electrophysiology procedures.
 
Both closure devices are CE marked under MDR for patients who have undergone catheter-based procedures with single or multiple access sites in one or both limbs and include proprietary, collapsible disc tech and a resorbable collagen patch to reach homeostasis. VASCADE and VASCADE MVP aim to save hospital staff time while helping patients achieve homeostasis more quickly and with fewer complications, on average, compared to manual compression.
 
“First and foremost, the VASCADE MVP system helps promote patient wellbeing. There is a very short post-procedural bedrest, which can reduce back pain and the need for urinary catheters and create the possibility for same-day discharge. From a handling perspective, the VASCADE MVP device is logical to operate and has smooth control. During the product evaluation, we achieved hemostasis in the EP lab without the need of any further compressive bandages,” Dr. Bogdan Muntean, Senior Physician of Cardiology and Medical Director of Electrophysiology at The Jewish Hospital in Berlin, told the press.
 
Haemonetics said it’s preparing further VASCADE portfolio expansion in markets outside the U.S. After the German launch, VASCADE systems were released in Italy. The company recently revealed VASCADE MVP distribution in Japan, courtesy of an exclusive agreement with Japan Lifeline Co.
 
Haemonetics said VASCADE MVP is expected to launch in Japan later this year.
 
“International commercialization of our VASCADE portfolio represents an exciting milestone for our vascular closure business, reinforcing our industry leadership in improving hospital operations and raising standards of care for patients,” said Stewart Strong, Haemonetics’ president of Global Hospital. “We look forward to continuing to expand our presence in global interventional cardiology and electrophysiology markets to meet the ongoing needs of physicians throughout the world.”